Conservative oxygen supplementation during helmet continuous positive airway pressure therapy in patients with COVID-19 and respiratory failure: a pilot study.
Journal
ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
20
07
2022
accepted:
08
12
2022
medline:
5
4
2023
entrez:
4
4
2023
pubmed:
5
4
2023
Statut:
epublish
Résumé
Respiratory failure is a severe complication in coronavirus disease 2019 (COVID-19) pneumonia that, in addition to oxygen therapy, may require continuous positive airway pressure (CPAP) support. It has been postulated that COVID-19 lung injury may share some features with those observed in hyperoxic acute lung injury. Thus, a correct target arterial oxygen tension ( This was a single-centre, historically controlled study of patients with severe respiratory failure due to COVID-19 pneumonia, receiving either conservative or nonconservative oxygen supplementation during helmet CPAP. A cohort receiving conservative oxygen supplementation was studied prospectively in which oxygen supplementation was administered with a target 71 patients were included in the conservative cohort and 75 in the nonconservative cohort. Mortality rate was lower in the conservative cohort (22.5% In patients with COVID-19 and severe respiratory failure, conservative oxygen supplementation during helmet CPAP was associated with improved survival, lower ICU admission rate and less new-onset organ failure.
Sections du résumé
Background
UNASSIGNED
Respiratory failure is a severe complication in coronavirus disease 2019 (COVID-19) pneumonia that, in addition to oxygen therapy, may require continuous positive airway pressure (CPAP) support. It has been postulated that COVID-19 lung injury may share some features with those observed in hyperoxic acute lung injury. Thus, a correct target arterial oxygen tension (
Methods
UNASSIGNED
This was a single-centre, historically controlled study of patients with severe respiratory failure due to COVID-19 pneumonia, receiving either conservative or nonconservative oxygen supplementation during helmet CPAP. A cohort receiving conservative oxygen supplementation was studied prospectively in which oxygen supplementation was administered with a target
Results
UNASSIGNED
71 patients were included in the conservative cohort and 75 in the nonconservative cohort. Mortality rate was lower in the conservative cohort (22.5%
Conclusions
UNASSIGNED
In patients with COVID-19 and severe respiratory failure, conservative oxygen supplementation during helmet CPAP was associated with improved survival, lower ICU admission rate and less new-onset organ failure.
Identifiants
pubmed: 37013111
doi: 10.1183/23120541.00455-2022
pii: 00455-2022
pmc: PMC9790093
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright ©The authors 2023.
Déclaration de conflit d'intérêts
Conflict of interest: None declared.
Références
N Engl J Med. 2021 Apr 8;384(14):1301-1311
pubmed: 33471452
Eur J Intern Med. 2021 Oct;92:48-54
pubmed: 34175182
JAMA. 2016 Oct 18;316(15):1583-1589
pubmed: 27706466
Crit Care. 2014 Dec 23;18(6):711
pubmed: 25532567
Front Physiol. 2020 Aug 04;11:947
pubmed: 32848874
Respir Care. 2016 Jun;61(6):801-17
pubmed: 27235315
Eur Respir J. 2021 Mar 25;57(3):
pubmed: 33767005
Ann Intensive Care. 2015 Dec;5(1):42
pubmed: 26585328
Am J Respir Crit Care Med. 2020 Sep 1;202(5):690-699
pubmed: 32667207
Shock. 2014 Aug;42(2):148-53
pubmed: 24978892
Am J Physiol Lung Cell Mol Physiol. 2020 Oct 1;319(4):L670-L674
pubmed: 32878480
Crit Care. 2021 Dec 19;25(1):440
pubmed: 34924022
Can Respir J. 2020 May 6;2020:3953280
pubmed: 32454913
Am J Physiol Lung Cell Mol Physiol. 2021 Jan 1;320(1):L12-L16
pubmed: 33050737
Cells. 2021 Jul 26;10(8):
pubmed: 34440665
Respir Care. 2013 Jan;58(1):123-41
pubmed: 23271823
Free Radic Biol Med. 2020 Nov 20;160:13-18
pubmed: 32768569
J Immunol. 2003 Jul 15;171(2):955-63
pubmed: 12847267
Diabetes Obes Metab. 2020 Oct;22(10):1915-1924
pubmed: 32573903
Lancet. 2018 Apr 28;391(10131):1693-1705
pubmed: 29726345
Am J Respir Crit Care Med. 2005 Feb 15;171(4):388-416
pubmed: 15699079
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
ERJ Open Res. 2021 Apr 06;7(2):
pubmed: 33847695
Histopathology. 2020 Aug;77(2):198-209
pubmed: 32364264
N Engl J Med. 2020 Mar 12;382(11):999-1008
pubmed: 32160661
Chest. 1973 May;63(5):793-800
pubmed: 4703635